US drug approval numbers fall despite pharma investing more in R&D
Stricter FDA policies are partly to blame for the decline says GBI Research
Read More
Section: Sales
Pfizer gets US approval for leukaemia drug Bosulif
FDA grants the tyrosine kinase inhibitor a licence to treat chronic myelogenous leukaemia
Read More
IFPMA launches expanded code of practice
Clarifies guidelines on continuing medical education and gifts for doctors
Read More
Pfizer’s Inlyta gets EU approval for advanced kidney cancer
Available as second-line therapy after treatment with pharma firm’s own Sutent
Read MoreValeant offers $2.6bn to buy dermatology firm Medicis
Possible further addition to long list of Canadian pharma firm’s acquisitions
Read More